Neutron activation of NDDP, a liposomal platinum antitumor agent

Cancer Biotherapy and Radiopharmaceuticals

Volumn 15, Issue 3, 2000, Pages 253-259

  MacLean, Donald S ^a,c   Khokhar, Abdul R ^a   Perez Soler, Roman ^a,b  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF KANSAS   (United States)

Author keywords

Drug stability; Lipophilic platinum complex; Liposome; Neutron activation analysis

Indexed keywords

ANTINEOPLASTIC AGENT; PLATINUM 1,2 DIAMINOCYCLOHEXANE MALONATE;

ARTICLE; CANCER; DRUG DISTRIBUTION; DRUG PENETRATION; IRRADIATION; LIPOPHILICITY; NEUTRON ACTIVATION ANALYSIS; NUCLEAR REACTOR; PRIORITY JOURNAL;

EID: 0033854214     PISSN: 10849785     EISSN: None     Source Type: Journal    
DOI: 10.1089/108497800414347     Document Type: Article

References (24)

1. Han I, Khokhar AR, Perez-Soler R. Intraliposomal conversion of lipophilic cis-bis-carboxylato-trans-R, R-1,2-diaminocyclohexane-platinum (II) complexes into cis-bis-dichloro-trans-R, R-1, 2-diaminocyclohexane-platinum (II). Cancer Chemother Pharmacol 1996; 39 (1-2): 17.
2. Khokhar AR, Al-Baker S, Brown T, Perez-Soler R. Chemical and biological studies on a series of lipid-soluble (trans-(R,R)-and (S,S)-1,2-diaminocyclohexane) platinum(II) complexes incorporated in liposomes, J Med Chem 1991; 34 (1): 325.
3. Khokhar AR, Al-Baker S, Perez-Soler R. Toxicity and efficacy studies on a series of lipid-soluble dineodecanoato(trans-R,R-and trans-S,S-1,2-diaminocyclohexane)platinum(II) complexes entrapped in liposomes. Anticancer Drugs 1992; 3: 95.
4. Perez-Soler R, Khokhar AR, Lopez-Berestein G. Treatment and prophylaxis of experimental liver metastases of M5076 reticulosarcoma with cis-bis-neodecanoato-trans-R,R-1,2-diaminocyclohexaneplatinum (II) encapsulated in multilamellar vesicles, Cancer Res 1987; 47: 6462.
5. Perez-Soler R, Lopez-Berestein G, Lautersztain J, et al. Phase I clinical and pharmacological study of liposome entrapped cis-bis-neodecanoato-trans-R,R-1,2-diamminocyclohexaneplatinum (II). Cancer Res 1990; 50: 4254.
6. Perez-Soler R, Han I, Al-Baker S, Khokhar AR. Lipophilic platinum complexes entrapped in liposomes: improved stability and preserved antitumor activity with complexes containing linear alkyl carboxylato leaving groups. Cancer Chemother Pharmacol 1994; 33: 378.
7. Perez-Soler R, Shin DM, Siddik ZH, Murphy WK, Huber M, Lee JS, Khokhar AR, Hong WK. Phase I clinical and pharmacological study of liposome-entrapped NDDP administered intrapleurally in patients with malignant pleural effusions, Clin Cancer Res 1997; 3: 373.
8. Lévi F. Chronopharmacologie et chronothérapie des cancers. Pathologie Biologie 1996; 44 (7): 631.
9. Lévi F. Chromotherapy for gastrointestinal cancers. Curr Opin Oncol 1996; 8: 334.
10. Soulié P, Raymond E, Brienza S, Cvitkovic E, Oxaliplatine: le premier DACH platine en clinique. Bull Cancer 1997; 84 (6): 665.
11. Perez-Soler R, Yang LY, Drewinko B, Lautersztain J, Khokhar AR. Increased cytotoxicity and reversal of resistance to cis-diamminedichloroplatinum (II) with entrapment of cis-bis-neodecanoato-trans-R,R-1,2-diamminocyclohexane platinum (II) in multilamellar lipid vessels. Cancer Res 1988; 48: 4509.
12. Perez-Soler R, Khokhar AR. Lipophilic cisplatin analogues entrapped in liposomes: role of intraliposomal drug activation in biological activity. Cancer Res 1992; 52: 6341.
13. Seiler G, Sigel A, Sigel H (eds) Handbook on Metals in Clinical and Analytical Chemistry, New York, Marcel Dekker, Inc., 1994.
14. Akaboshi M, Kawai K, Maki H, Akuta K, Ujeno Y, Ono K, Miyahara T. Determination of the target volume of HeLa cells treated with platinum-195m radiolabeled trans-diaminodichloroplatinum (II): a comparison with cis-diaminodichloroplatinum (II). Nucl Med Biol 1993; 20 (4): 389.
15. Hoeschele JD, Butler TA, Roberts JA. Correlation of physico-chemical and biological properties with vivo biodistribution data for platinum-195m-labeled chloroammineplatinum(II) complexes. Inorg Chem Biol Med 1980; 140: 181.
16. DeSimone PA, Yancey RS, Coupal JJ, Butts JD, Hoeschel JD. Effect of a forced diuresis on the distribution and excretion (via urine and bile) of 195m platinum when given as 195m platinum cis-dichlorodiamineplatinum (II). Cancer Treatment Reports 1979; 63 (6): 951.
17. Bénard P, Desplanches G, Macquet JP, Simon J. Whole-body autoradiographic study of the distribution of 195m-Pt in healthy and tumor-bearing mice treated with labeled cisplatin. Cancer Treatment Reports 1983; 67 (5): 457.
18. Robins AB, Leach MO. Pharmacokinetics of therapeutic doses of isotopically labeled platinum antitumor agents in the mouse and rat. Cancer Treatment Reports 1983; 67 (3):245.
19. Khokhar AR, Al-Baker S, Krakoff IH, Perez-Soler R. Toxicity and antitumor activity of cis-bis-carboxylato(trans-R,R-1,2-diaminocyclohexane)platinum (II) Complexes entrapped in liposomes. Cancer Chemother Pharmacol 1989; 23: 219.
20. Perez-Soler R, Francis K, Al-Baker S, Pilkiewicz F, Khokhar AR. Preparation and characterization of liposomes containing a lipophilic cisplatin derivative for clinical use. J Microencapsul 1994; 11 (1): 41.
21. Chaney SG, Wyrick SD, Till GK. In vitro biotransformations of tetrachloro(d,1-trans)-1,2-diaminocyclohexaneplatinum(IV) (tetraplatinum) in rat plasma. Cancer Res 1990; 50: 4539.
22. Screnci D, Er HM, Hambley TW, Galettis P, Brouwer W, McKeage MJ. Stereoselective peripheral sensory neurotoxicity of diaminocyclohexane platinum enantiomers related to ormaplatin and oxaliplatin. Br J Cancer 1997; 76 (4): 502.
23. Mauldin SK, Gibbons G, Wyrick SD, Chaney SG. Intracellular biotransformation of platinum compounds with the 1,2-diaminocyclohexane carrier ligand in the L1210 cell line. Cancer Res 1988; 48: 5136.
24. Mauldin SK, Plescia M, Richard FA, Wyrick SD, Voyksner RD, Chaney SG. Displacement of the bidentate malonate ligand from (d,1-1,2-diaminocyclohexane) malonateplatinum(II) by physiologically important compounds in vitro. Biochem Pharmacol 1988; 37 (17): 3321.